Brokerages forecast that Akebia Therapeutics Inc (NASDAQ:AKBA) will announce earnings per share of ($0.35) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Akebia Therapeutics’ earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.41). Akebia Therapeutics reported earnings per share of ($0.60) in the same quarter last year, which would indicate a positive year-over-year growth rate of 41.7%. The company is scheduled to report its next earnings report on Wednesday, August 14th.
On average, analysts expect that Akebia Therapeutics will report full-year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.41). For the next fiscal year, analysts forecast that the company will report earnings of ($0.63) per share, with EPS estimates ranging from ($1.66) to $0.38. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Akebia Therapeutics.
Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.02). The business had revenue of $72.67 million during the quarter, compared to analysts’ expectations of $83.69 million. Akebia Therapeutics had a negative net margin of 82.14% and a negative return on equity of 45.06%.
Large investors have recently added to or reduced their stakes in the business. Baupost Group LLC MA bought a new position in Akebia Therapeutics during the 4th quarter worth approximately $135,327,000. Strs Ohio lifted its holdings in Akebia Therapeutics by 70.5% during the 4th quarter. Strs Ohio now owns 42,800 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 17,700 shares during the last quarter. Alps Advisors Inc. lifted its holdings in Akebia Therapeutics by 118.3% during the 4th quarter. Alps Advisors Inc. now owns 220,395 shares of the biopharmaceutical company’s stock worth $1,219,000 after buying an additional 119,447 shares during the last quarter. Adell Harriman & Carpenter Inc. bought a new position in Akebia Therapeutics during the 4th quarter worth approximately $116,000. Finally, Boston Partners bought a new position in Akebia Therapeutics during the 4th quarter worth approximately $1,545,000. 70.62% of the stock is currently owned by institutional investors.
Shares of AKBA opened at $4.31 on Thursday. Akebia Therapeutics has a one year low of $4.12 and a one year high of $11.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.71 and a quick ratio of 1.15.
About Akebia Therapeutics
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.